Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215534 | 0.99 | CYP11B2 (0.46) | CYP11B2CYP11B1PDE3BPDE3AP2RY12 | |
| SCHEMBL2212909 | 0.93 | PDE3B (0.45) | CYP11B2CYP11B1PDE3BPDE3AP2RY12 | |
| SCHEMBL2215788 | 0.92 | PDE3B (0.45) | CYP11B2CYP11B1PDE3BPDE3AP2RY12 | |
| SCHEMBL2214154 | 0.92 | G6PD (0.47) | CYP11B2CYP11B1PDE3BPDE3AP2RY12 | |
| SCHEMBL2212602 | 0.91 | GBA1 (0.48) | CYP11B2CYP11B1PDE3BPDE3AP2RY12 | |
| SCHEMBL1378188 | 0.91 | CYP11B2 (0.46) | CYP11B2CYP11B1PDE3BPDE3APDE2A | |
| SCHEMBL2818063 | 0.91 | G6PD (0.45) | CYP11B2CYP11B1PDE3BPDE3AP2RY12 | |
| SCHEMBL2213278 | 0.90 | CYP11B2 (0.45) | CYP11B2CYP11B1PDE3BPDE3AP2RY12 | |
| SCHEMBL2819720 | 0.90 | G6PD (0.48) | CYP11B2CYP11B1PDE3BPDE3AP2RY12 | |
| SCHEMBL6618630 | 0.87 | CYP11B2 (0.52) | CYP11B2CYP11B1PDE2AG6PDAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474415-B1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | BAYER SCHERING PHARMA AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7683081-B2 | 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-23 | — | — | US | disclosed |
| US-20050267160-A1 | 1-Phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-01 | — | — | US | disclosed |
| US-6962932-B2 | 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-11-08 | — | — | US | disclosed |
| EP-1474415-A1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | Schering Aktiengesellschaft (DE) | 2004-11-10 | — | — | EP | disclosed |
| US-20030229085-A1 | 1-Phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-12-11 | — | — | US | disclosed |
| WO-2003068766-A1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267160-A1 | 1-Phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | CD4, NFATC1, ICOS | CYP11B2 512/4885CYP11B1 918/4885PDE3B 644/4885 |
| US-20030229085-A1 | 1-Phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | CD4, ICOS, NFATC1 | CYP11B2 349/4885CYP11B1 595/4885PDE3B 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.